MavriX Bio
PrivateLast Round
Corporate Funding
Feb 14, 2025
Company Overview
MavriX Bio is a biotechnology company developing gene replacement therapies for the treatment of Angelman syndrome.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MavriX Bio Comparables
Compare MavriX Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Encoded Therapeutics | 88% | |
| Oak Hill Bio | 83% | |
| Couragene | 78% |
MavriX Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Feb 14, 2025 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 14, 2025
Led by Foundation for Angelman Syndrome Therapeutics and AS²Bio Inc.
MavriX Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about MavriX Bio's valuation, stock price, and market status.
Is MavriX Bio a public or private company?
MavriX Bio is a private company.
What is the current stock price of MavriX Bio?
MavriX Bio is a private company with no public stock price. No recent secondary market data is available.
How much is MavriX Bio worth (valuation)?
Valuation information for MavriX Bio is not publicly available.
Can I buy MavriX Bio stock?
MavriX Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was MavriX Bio's last funding round?
MavriX Bio's most recent funding round was Corporate Funding on February 14, 2025.
Who are the main investors in MavriX Bio?
Investor information for MavriX Bio is not publicly disclosed.
Will MavriX Bio IPO soon?
No public IPO plans have been announced for MavriX Bio.
How can I track MavriX Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MavriX Bio's secondary market activity and sign up for updates.